Alpha 2.0
Login Register
» Authors » Alaa H M Abdelrahman

Alaa H M Abdelrahman

Explore the profile of Alaa H M Abdelrahman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 376
Followers 0
Related Specialties
Biochemistry
Biology
Molecular Biology
Top 10 Co-Authors
Mahmoud A A Ibrahim
Mohamed-Elamir F Hegazy
Peter A Sidhom
Khlood A A Abdeljawaad
Gamal A H Mekhemer
Paul W Pare
Mahmoud F Moustafa
Mohamed A M Atia
Ahmed M Shawky
Mahmoud E S Soliman
Published In
J Biomol Struct Dyn
PLoS One
Molecules
J Mol Graph Model
Pharmaceuticals (Basel)
Affiliations
Soon will be listed here.
Recent Articles
1.
Potential P-glycoprotein (P-gp) inhibitors from SuperDRUG2 database toward reversing multidrug resistance in cancer treatment: Database mining, molecular dynamics, and binding energy estimations
Abdeljawaad K, Abdelrahman A, Sidhom P, Tallima H, Shoeib T, Mekhemer G, et al.
J Mol Graph Model . 2025 Mar; 137:108997. PMID: 40043638
P-glycoprotein (P-gp) transporter is included in the failure of various carcinoma chemotherapeutics because of the multidrug resistance (MDR) phenomenon, in which the chemotherapeutic drugs are eliminated from target cells. Consequently,...
2.
Benzothiazinone analogs as Anti-Mycobacterium tuberculosis DprE1 irreversible inhibitors: Covalent docking, validation, and molecular dynamics simulations
Ibrahim M, Mahmoud D, Abdelrahman A, Abdeljawaad K, Mekhemer G, Shoeib T, et al.
PLoS One . 2024 Nov; 19(11):e0314422. PMID: 39585898
Mycobacterium tuberculosis is a lethal human pathogen, with the key flavoenzyme for catalyzing bacterial cell-wall biosynthesis, decaprenylphosphoryl-D-ribose oxidase (DprE1), considered an Achilles heal for tuberculosis (TB) progression. Inhibition of DprE1...
3.
Repurposing of drug candidates against Epstein-Barr virus: Virtual screening, docking computations, molecular dynamics, and quantum mechanical study
Ibrahim M, Hassan A, Mohamed E, Mekhemer G, Sidhom P, El-Tayeb M, et al.
PLoS One . 2024 Nov; 19(11):e0312100. PMID: 39546470
Epstein-Barr virus (EBV) was the first tumor virus identified in humans, and it is mostly linked to lymphomas and cancers of epithelial cells. Nevertheless, there is no FDA-licensed drug feasible...
4.
Exploring marine natural products for identifying putative candidates as EBNA1 inhibitors: An insight from molecular docking, molecular dynamics, and DFT computations
Ibrahim M, Hassan A, Mekhemer G, Sidhom P, El-Tayeb M, Abdelbacki A, et al.
Biochem Biophys Res Commun . 2024 Oct; 735:150856. PMID: 39437701
Epstein-Barr virus (EBV), namely a DNA neoplasm virus, is liable for over 1 % of malignant neoplasms involving Hodgkin's and Burkitt's lymphoma as well as ventral cancer. Despite the crucial...
5.
Naturally Occurring Plant-Based Anticancerous Candidates as Potential ERK2 Inhibitors: In-Silico Database Mining and Molecular Dynamics Simulations
Ibrahim M, Ali S, Abdelrahman A, Abdeljawaad K, Sidhom P, Sayed S, et al.
Chem Biodivers . 2024 Jul; 21(11):e202401238. PMID: 39075025
The evolutionarily conserved extracellular signal-regulated kinase 2 (ERK2) is involved in regulating cellular signaling in both normal and pathological conditions. ERK2 expression is critical for human development, while hyperactivation is...
6.
Pyronaridine as a Bromodomain-Containing Protein 4--Terminal Bromodomain (BRD4-BD1) Inhibitor: Database Mining, Molecular Docking, and Molecular Dynamics Simulation
Ibrahim M, Abdelhamid M, Abdeljawaad K, Abdelrahman A, Mekhemer G, Sidhom P, et al.
Molecules . 2023 Aug; 28(15). PMID: 37570684
BRD4 (bromodomain-containing protein 4) is an epigenetic reader that realizes histone proteins and promotes the transcription of genes linked to cancer progression and non-cancer diseases such as acute heart failure...
7.
In-Silico Mining of the Toxins Database (T3DB) towards Hunting Prospective Candidates as ABCB1 Inhibitors: Integrated Molecular Docking and Lipid Bilayer-Enhanced Molecular Dynamics Study
Ibrahim M, Abdeljawaad K, Abdelrahman A, Sidhom P, Tawfeek A, Mekhemer G, et al.
Pharmaceuticals (Basel) . 2023 Jul; 16(7). PMID: 37513931
Multidrug resistance (MDR) is one of the most problematic issues in chemotherapeutic carcinoma therapy. The ABCB1 transporter, a drug efflux pump overexpressed in cancer cells, has been thoroughly investigated for...
8.
SuperNatural inhibitors to reverse multidrug resistance emerged by ABCB1 transporter: Database mining, lipid-mediated molecular dynamics, and pharmacokinetics study
Ibrahim M, Abdeljawaad K, Abdelrahman A, Abdelhamid M, Naeem M, Mekhemer G, et al.
PLoS One . 2023 Jul; 18(7):e0288919. PMID: 37494356
An effective approach to reverse multidrug resistance (MDR) is P-glycoprotein (P-gp, ABCB1) transport inhibition. To identify such molecular regulators, the SuperNatural II database, which comprises > 326,000 compounds, was virtually...
9.
Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an drug discovery study
Ibrahim M, Abdeljawaad K, Jaragh-Alhadad L, Oraby H, Atia M, Alzahrani O, et al.
J Biomol Struct Dyn . 2023 Mar; 41(23):13977-13992. PMID: 36883864
The failure of chemotherapy in the treatment of carcinoma is mainly due to the development of multidrug resistance (MDR), which is largely caused by the overexpression of P-glycoprotein (P-gp/ABCB1/MDR1). Until...
10.
In silico drug discovery of SIRT2 inhibitors from natural source as anticancer agents
Ibrahim M, Abdeljawaad K, Roshdy E, Mohamed D, Ali T, Gabr G, et al.
Sci Rep . 2023 Feb; 13(1):2146. PMID: 36750593
Sirtuin 2 (SIRT2) is a member of the sirtuin protein family, which includes lysine deacylases that are NAD-dependent and organize several biological processes. Different forms of cancer have been associated...